Vanda (VNDA) Q1 2026 earnings review
Heavy Commercial Investments Drive Accelerating Cash Burn
Vanda has fully pivoted into a commercial spending phase to support a ballooning product portfolio. Total Q1 revenue grew a meager 3% YoY, but net loss swelled to $48.6M as SG&A expenses surged 36% to fund the Fanapt bipolar expansion and the NEREUS launch. While management successfully achieved the BYSANTI approval and raised FY26 guidance by $10M-$30M due to the novel NEREUS direct-to-consumer launch, the financial toll is steep. Cash balances plunged by $61.5M in a single quarter, leaving the company with $202.3M. Management is betting the balance sheet on its ability to rapidly accelerate top-line growth.
🐂 Bull Case
The NEREUS launch via a proprietary direct-to-consumer site (nereus.us) bypasses traditional pharmacy hurdles, immediately adding $10-$30M to FY26 guidance and establishing a highly scalable distribution model.
The FDA approval of BYSANTI for Bipolar I and Schizophrenia secures a critical asset with data exclusivity through 2031, effectively de-risking Vanda's late-decade revenue cliff.
🐻 Bear Case
A $61.5M quarterly cash drop suggests Vanda has ~4-5 quarters before a raise is needed, assuming cash burn remains at these elevated levels.
Fanapt weekly prescriptions hit 11-year highs, yet Q1 revenue reversed sequentially. Volume gains are being erased by aggressive co-pay support and systemic rebate pressures.
⚖️ Verdict: 🔴
Bearish. Management is building an impressive portfolio of approved drugs, but commercial execution costs are bleeding the balance sheet. Vanda must prove its massive SG&A expansion can yield proportionate net revenue growth before the cash runs out.
Key Themes
Fanapt's Curious Sequential Decline
Management praised Fanapt's 32% YoY TRx growth and 76% NBRx surge, noting weekly scripts reached an 11-year high. However, actual Q1 revenue fell sequentially from $33.2M in 25Q4 to $29.6M in 26Q1. This Reversing trend exposes a massive contradiction: explosive volume growth is not translating to the top line, heavily implying severe gross-to-net margin deterioration from aggressive co-pay support to capture market share.
The NEREUS Direct-to-Consumer Disruption
The launch of NEREUS (tradipitant) for motion sickness via the nereus.us platform is a fascinating commercial experiment. By utilizing an online platform with rapid direct home delivery, Vanda is circumventing traditional PBM and specialty pharmacy bottlenecks. This tech-enabled strategy represents a core growth driver and immediately added $10-$30M to FY26 guidance.
IRA Squeezing Gross-to-Net
The structural pressure on the legacy portfolio is compounded by macroeconomic factors. As flagged in prior quarters, the Inflation Reduction Act (IRA) Medicare benefit redesign—specifically the fee increase from 1% in 2025 to 2% in 2026—is actively compressing the net realized price across Vanda's commercial assets, helping explain the disconnect between volume and sales.
The SG&A Cash Furnace
Vanda's commercial buildout is punishing the bottom line. SG&A spiked 36% YoY to $68.4M. Combined with a $10M milestone to Eli Lilly, the company torched $61.5M in cash this quarter. At this Accelerating burn rate, Vanda will face existential liquidity questions within 12 months unless revenue scales dramatically.
Regulatory Clean Sweep
Vanda's R&D engine is delivering. BYSANTI received FDA approval for Bipolar I/Schizophrenia in February 2026. Furthermore, the Imsidolimab BLA for Generalized Pustular Psoriasis (GPP) was accepted with a December 2026 PDUFA date. The transition from a clinical-stage pipeline to a broad commercial portfolio is Accelerating.
Other KPIs
Down steeply from $263.8M at the end of 2025. This $61.5M sequential drop (which includes a $10M milestone to Lilly) represents a Decelerating runway that requires immediate monitoring.
Decelerating from $35.7M a year ago. Management is clearly shifting capital allocation away from clinical discovery and heavily toward SG&A for product commercialization.
Decelerating further, down 24% YoY. Generic erosion continues to destroy the former flagship product's market share, emphasizing the absolute necessity of the NEREUS and Fanapt launches succeeding.
Guidance
Accelerating. Raised from the prior $230-$260M range specifically to include the NEREUS launch. The midpoint ($265M) implies a healthy 22% YoY growth compared to FY25's $216.1M.
Accelerating. The range remains unchanged, implying ~36% YoY growth at the midpoint vs FY25. However, achieving this requires a steep sequential ramp given the soft $29.6M run rate generated in 26Q1.
Accelerating. A completely new guidance metric. Represents the expected contribution from the novel DTC commercial platform in its first ~3 quarters on the market.
Key Questions
Gross-to-Net Reversion
Fanapt's Q1 sequential revenue fell by over $3M despite TRx reaching 11-year highs. Exactly how much of your gross-to-net degradation is permanent versus timing-related from Q1 co-pay support?
Cash Runway Management
At a $60M+ quarterly cash burn rate, your $202M cash pile provides less than a year of runway. Do you plan to tap the equity markets, or will OpEx organically scale down in H2 2026?
DTC Economics
What are the customer acquisition costs (CAC) looking like for the NEREUS direct-to-consumer platform, and when do you project that specific distribution channel will turn cash-flow positive?